1. Introduction

Artificial intelligence (AI) is increasingly important in biotechnology laboratories. It can be used to analyse genomic sequences, identify genetic mutations, develop pharmaceutical compounds, predict biological reactions, automate laboratory experiments and support medical diagnosis.

In Morocco, the integration of AI into biotechnology laboratories raises important legal questions concerning:

Protection of genetic and biological information.

Patient consent and confidentiality.

Algorithmic accuracy and scientific reliability.

Liability for AI-generated laboratory errors.

Regulation of genetically modified organisms.

Cybersecurity of laboratory information systems.

Human supervision of automated scientific decisions.

Protection of intellectual property.

Ethical approval of biomedical research.

Accountability of biotechnology institutions.

An important legal distinction: Morocco does not have a comprehensive, dedicated AI statute specifically regulating biotechnology laboratories. Instead, AI-based laboratory activities are governed by existing legislation on personal data, biomedical research, medicines, medical laboratories, cybersecurity and environmental protection.

This creates a framework in which AI is regulated through the legal consequences of its use rather than through a single AI-specific regulatory code.

KaperX+2

2. Constitutional and Legal Foundations

The Moroccan Constitution of 2011 provides important foundations for regulating AI-based biotechnology.

Article 24 – Right to Privacy

Article 24 protects the right to private life.

This protection is particularly relevant where biotechnology laboratories use AI to process:

Human DNA sequences.

Genetic inheritance information.

Personal medical histories.

Reproductive health information.

Biological samples connected to identifiable individuals.

Predictive genetic risk assessments.

A laboratory cannot treat genetic information as ordinary technical data when it identifies or relates to an individual.

Article 27 – Right to Information

Article 27 recognises the right of access to information, subject to constitutional and statutory limitations.

In AI-assisted biotechnology, this principle supports transparency concerning public research, regulatory activities and the use of scientific technologies, while respecting medical confidentiality and personal-data protection.

cndp.ma

3. Law No. 09-08: Personal Data Protection

Major applicable legislation

Law No. 09-08, promulgated by Dahir No. 1-09-15 of 18 February 2009, is one of the most important legal instruments governing AI integration in Moroccan biotechnology laboratories.

It protects individuals in relation to the processing of personal data.

The National Commission for the Control of Personal Data Protection (CNDP) supervises compliance.

A. Application to AI biotechnology

Suppose a Moroccan biotechnology laboratory develops an AI platform that analyses 20,000 human genetic profiles to identify hereditary diseases.

The laboratory may be processing sensitive personal information.

Its activities must therefore comply with applicable requirements concerning:

Lawful processing.

Appropriate legal grounds.

Purpose limitation.

Data accuracy.

Data confidentiality.

Security safeguards.

Individual rights.

Applicable CNDP declarations or authorisations.

B. Automated decision-making

Article 11 of Law No. 09-08 is particularly relevant.

It restricts decisions based solely on automated processing that evaluate certain personal characteristics or behaviour and have legal effects or significantly affect individuals, subject to the statutory exceptions.

For example, a biotechnology laboratory should not allow an AI system to make an exclusively automated determination that a patient is genetically unsuitable for a treatment where that determination has significant legal consequences.

Meaningful human involvement and the opportunity for the individual to present their position are important safeguards.

C. Cross-border genetic information

If a Moroccan laboratory transfers genetic datasets to a foreign AI development company, international data-transfer requirements under Law No. 09-08 must also be considered.

This is especially important when cloud-based AI platforms are hosted outside Morocco.

cndp.ma+2

4. Regulation of Biomedical Research

Morocco's biomedical research framework is also relevant to AI-based biotechnology experiments.

The Ministry of Health identifies ministerial decisions dated 29 March 2012 and 3 December 2012 concerning biomedical research.

These instruments provide an important regulatory context for research involving human participants.

Important compliance requirements

AI-assisted biomedical research should address:

Scientific justification for the research.

Ethical review where required.

Appropriate participant information and consent.

Protection of biological samples.

Confidentiality of research records.

Scientific validity of AI-generated results.

Responsible supervision by qualified researchers.

For example, an AI system designed to predict genetic susceptibility to cancer must not be treated as a substitute for appropriate scientific validation and clinical oversight.

IRC+1

5. Regulation of Medical and Biotechnology Laboratories

A. Law No. 12-01: Private Medical Biology Laboratories

Law No. 12-01 regulates private medical biology analysis laboratories in Morocco, together with its implementing Decree No. 2-05-752 of 13 July 2005.

This legislation is relevant when AI is integrated into medical laboratory activities, including:

Automated blood analysis.

Genetic testing.

Molecular diagnostics.

Detection of infectious diseases.

Laboratory interpretation of clinical samples.

AI-assisted identification of biological abnormalities.

AI software does not remove the laboratory's underlying regulatory responsibilities.

A laboratory must continue to comply with applicable professional, technical and operational requirements.

B. Law No. 11-08: In Vitro Diagnostic Reagents

Law No. 11-08 concerns reagents used for in vitro diagnosis.

Its implementing framework includes Decree No. 2-12-149 of 25 April 2012.

This legislation becomes relevant when AI biotechnology platforms depend on diagnostic reagents or associated testing procedures.

For example, an AI-enabled diagnostic platform combining molecular testing and algorithmic interpretation must satisfy the applicable requirements governing its diagnostic components.

C. Law No. 84-12: Medical Devices

Law No. 84-12 regulates medical devices.

Where AI software forms part of a medical device or its diagnostic functionality, the applicable medical-device regulatory requirements must be examined.

The legal question is whether the software is merely a laboratory research tool or performs a regulated medical-device function.

These distinctions are important because research software and clinical diagnostic software may have different regulatory consequences.

sante.gov.ma+1

6. Biosafety and Artificial Intelligence Integration

Morocco is a party to the Cartagena Protocol on Biosafety, which entered into force internationally on 11 September 2003.

Morocco ratified the Protocol on 25 April 2011, and it entered into force for Morocco on 24 July 2011.

The Department of Sustainable Development acts as the national focal point, while the National Office for Food Safety (ONSSA) has been designated as the competent national authority for the relevant administrative functions.

treaties.un.org+1

A. AI and genetically modified organisms

AI can be used to:

Design genetic modifications.

Predict gene-expression patterns.

Analyse genetic mutations.

Model the environmental effects of modified organisms.

Identify potential biological hazards.

Monitor laboratory containment systems.

These applications create biosafety concerns.

For example, an AI platform might predict that a genetically modified microorganism is unlikely to survive outside a controlled laboratory.

If the prediction is inaccurate and the organism escapes, questions arise concerning laboratory negligence, containment procedures and environmental responsibility.

B. Absence of a comprehensive domestic GMO statute

An important limitation in Morocco's regulatory framework is that the national biosafety information system reports that Morocco has not established a comprehensive domestic law governing living modified organisms.

It also records the historical establishment of a National Biosafety Committee and earlier proposals for dedicated legislation.

Consequently, the Cartagena Protocol and applicable domestic environmental, agricultural and health legislation must be considered together.

A laboratory should not interpret the absence of a comprehensive GMO statute as unrestricted permission to conduct genetic engineering or environmental releases.

Morocco+1

7. Cybersecurity Regulation of AI Biotechnology Laboratories

Law No. 05-20 on Cybersecurity is relevant to certain information systems operated by public entities and critical infrastructure operators.

Biotechnology laboratories may become subject to its requirements depending on their institutional status and the classification of their information systems.

AI-based laboratory infrastructure may contain:

Genetic databases.

Patient identification records.

Pharmaceutical research information.

Proprietary biological models.

Clinical-trial information.

Research algorithms.

Sensitive laboratory operational data.

Legal responsibilities

Relevant institutions should consider:

Access-control mechanisms.

Protection against unauthorised access.

Secure storage of genetic information.

System integrity.

Appropriate backup procedures.

Cyberattack prevention.

Protection of research infrastructure.

An AI system that produces incorrect results because of manipulated laboratory data can create both scientific and legal risks.

Law No. 07-03, concerning offences relating to automated data-processing systems, may also become relevant where cybercriminal conduct affects laboratory systems.

Responsible AI Guide+1

8. Intellectual Property Rights and AI-Generated Biotechnology Inventions

AI integration also raises intellectual property questions.

Morocco's Law No. 17-97 on the Protection of Industrial Property, as amended, is relevant to patents and industrial property.

Law No. 2-00 on Copyright and Related Rights is relevant to qualifying software and other protected works.

A. AI-designed genetic inventions

Consider a Moroccan laboratory using AI to identify a new biological molecule.

Important questions include:

Who owns the resulting invention?

Can the invention satisfy patentability requirements?

Who qualifies as the inventor?

Can the laboratory claim ownership of AI-generated results?

How should confidential training datasets be protected?

Does the invention involve pre-existing patented technology?

B. Human contribution

The use of AI does not automatically establish that an AI system can hold patent rights or be recognised as an inventor.

The patent application must be assessed under the applicable Moroccan industrial-property framework.

Human researchers, institutions and contractual arrangements may therefore play important roles in determining ownership and inventorship.

9. Liability for AI-Generated Laboratory Errors

One of the most significant legal issues is responsibility when AI produces an incorrect scientific result.

Consider the following hypothetical situation:

A Moroccan biotechnology laboratory uses an AI-based genetic diagnostic system. The system incorrectly identifies a patient as carrying a hereditary disease. The laboratory communicates this result without adequate verification, causing serious consequences for the patient.

Potential legal responsibilities may involve:

The applicable legal basis will depend on the facts, contractual relationships, professional rules and evidence of fault and causation.

A. Negligence

A laboratory may face civil liability if it fails to exercise the care required by applicable professional and legal standards.

B. Product liability

Where defective software forms part of a regulated product, the relevant product-safety and liability framework must be examined.

C. Professional responsibility

Human researchers and medical professionals cannot automatically transfer their professional responsibilities to an AI platform.

D. Evidentiary responsibility

A laboratory should preserve:

Original biological test results.

AI-generated outputs.

Model versions.

Relevant input data.

Human review records.

Validation reports.

Audit trails.

These records can become essential evidence in litigation.

10. Case Laws and Judicial Principles

Important qualification: There is no established body of publicly reported Moroccan judicial decisions specifically concerning AI integration in biotechnology laboratories. The following cases are therefore comparative authorities. They help explain relevant legal principles but are not binding Moroccan precedents.

Case 1. S. and Marper v. United Kingdom (2008)

European Court of Human Rights · Applications Nos. 30562/04 and 30566/04 · 4 December 2008

Facts:

The case concerned the retention of fingerprints, cellular samples and DNA profiles of individuals who had not been convicted of criminal offences.

Judgment:

The European Court of Human Rights found a violation of Article 8 of the European Convention on Human Rights, concerning respect for private life.

Legal principle:

The retention of biological and genetic information must respect privacy and proportionality.

Relevance to Morocco:

A Moroccan biotechnology laboratory collecting DNA samples for AI-based research should establish appropriate purposes, lawful processing arrangements, retention periods and confidentiality safeguards.

Case 2. SCHUFA Holding (Scoring), Case C-634/21 (2023)

Court of Justice of the European Union · Judgment of 7 December 2023

Facts:

The dispute concerned automated credit scoring and the extent to which an algorithmically generated score could constitute automated decision-making under European data-protection law.

Judgment:

The Court clarified that the automated creation of a score can itself constitute automated individual decision-making where the score plays a determining role in a third party's decision.

Legal principle:

Automated profiling cannot necessarily be separated from the consequential decision that relies on it.

Relevance to Morocco:

Article 11 of Law No. 09-08 makes this principle particularly useful when evaluating AI-generated genetic risk scores, treatment eligibility assessments and other consequential biotechnology decisions.

The Moroccan statutory provisions must, however, be interpreted independently of the GDPR.

Case 3. Nowak v. Data Protection Commissioner, Case C-434/16 (2017)

Court of Justice of the European Union · Judgment of 20 December 2017

Facts:

The case concerned whether examination scripts and examiner comments constituted personal data.

Judgment:

The Court recognised that information connected to an identifiable individual may constitute personal data even where it takes the form of an assessment or evaluation.

Legal principle:

Personal data is not limited to conventional identity details. Evaluations and assessments relating to an individual can also qualify.

Relevance to Morocco:

AI-generated genetic interpretations, disease-risk scores and laboratory assessments linked to identifiable patients may constitute personal data under Law No. 09-08.

Case 4. Gaughran v. United Kingdom (2020)

European Court of Human Rights · Application No. 45245/15 · 13 February 2020

Facts:

The case involved the retention of biometric data, including fingerprints, DNA profiles and photographs, following a minor criminal conviction.

Judgment:

The Court found a violation of Article 8 because the retention framework did not provide sufficient safeguards.

Legal principle:

Biometric-data retention requires adequate safeguards and a proportionate legal framework.

Relevance to Morocco:

The case provides a useful comparative standard for evaluating long-term storage of genomic datasets and biological samples in AI research laboratories.

Case 5. European Court of Human Rights – Big Brother Watch and Others v. United Kingdom (2021)

Grand Chamber · Applications Nos. 58170/13, 62322/14 and 24960/15 · 25 May 2021

Facts:

The proceedings concerned large-scale surveillance and the collection and processing of communications information.

Judgment:

The Court examined safeguards against abuse in large-scale surveillance systems and found violations in aspects of the United Kingdom's surveillance framework.

Legal principle:

Large-scale data-processing systems require meaningful safeguards, oversight and protection against arbitrary interference.

Relevance to Morocco:

This principle is relevant when biotechnology laboratories use large-scale genomic datasets and AI systems to analyse populations.

It supports the importance of governance, access restrictions and accountability.

11. Regulatory Authorities and Institutional Responsibilities

Several Moroccan institutions may have responsibilities depending on the nature of the laboratory's activities.

cndp.ma+3

12. Major Legal Challenges

AI integration in Moroccan biotechnology laboratories presents several unresolved legal challenges.

A. Algorithmic discrimination

AI systems trained on incomplete genetic datasets may produce inaccurate predictions for particular population groups.

This raises concerns regarding equality, scientific reliability and discriminatory treatment.

B. Lack of explainability

Some AI systems operate through complex computational models.

Researchers may struggle to explain why a particular genetic diagnosis or biological prediction was generated.

C. Unclear liability

Existing legislation does not provide a comprehensive AI-specific liability framework allocating responsibility among developers, laboratory operators and researchers.

D. Genetic privacy

Genetic information can reveal information about biological relatives as well as the individual tested.

This creates complex confidentiality and consent issues.

E. International research collaboration

Moroccan laboratories increasingly have reasons to collaborate with foreign universities, pharmaceutical companies and AI developers.

Such arrangements can create cross-border data-transfer, intellectual-property and contractual compliance issues.

F. Regulatory fragmentation

The absence of a dedicated AI-biotechnology statute means that laboratories must consider multiple legal instruments simultaneously.

13. Recommended Compliance Framework for Moroccan Biotechnology Laboratories

A responsible laboratory should establish an AI governance programme covering the following areas.

Practical example

Suppose a biotechnology research centre in Casablanca develops an AI platform for detecting genetic diseases.

A legally responsible implementation should involve:

Establishing the legal basis for collecting genetic information.

Securing the required CNDP formalities.

Obtaining appropriate research ethics approval.

Ensuring the validity of the genetic testing methodology.

Testing the AI system for accuracy and bias.

Providing meaningful human supervision.

Protecting patient records against unauthorised access.

Establishing clear contractual responsibility with the AI developer.

Ensuring compliance with medical diagnostic requirements before clinical deployment.

Maintaining evidence of validation and laboratory decisions.

14. Recommendations for Reforming Moroccan AI Biotechnology Law

Morocco could strengthen its regulatory framework through the following reforms.

1. Dedicated AI biotechnology legislation

A specific legal framework could address AI applications in genomic research, molecular biology, pharmaceutical development and medical diagnostics.

2. Mandatory algorithmic audits

High-impact AI systems should undergo independent scientific and technical assessment.

3. Genetic-data protection standards

Specific safeguards could govern genomic databases, biological samples, genetic profiling and international research collaboration.

4. Clear liability rules

Legislation should clarify responsibility among AI developers, laboratory owners, researchers and medical professionals.

5. Human oversight

High-impact medical and biological decisions should remain subject to appropriate professional supervision.

6. AI research certification

Regulators could introduce risk-based certification requirements for AI systems used in clinical diagnostics and other sensitive biotechnology applications.

7. National biosafety coordination

The National Biosafety Committee and relevant authorities could strengthen coordination concerning AI-assisted genetic engineering and biological risk assessment.

15. Conclusion

The regulation of artificial intelligence integration in Moroccan biotechnology laboratories is developing through a combination of existing legal instruments rather than a single comprehensive AI statute.

Law No. 09-08 provides the principal foundation for protecting personal and genetic information. Law No. 12-01 regulates private medical biology laboratories, while Law No. 11-08 and Law No. 84-12 address relevant diagnostic and medical-device activities. Law No. 05-20 provides additional cybersecurity protection within its scope. The Cartagena Protocol establishes important international biosafety obligations.

The comparative judgments in S. and Marper, SCHUFA, Nowak, Gaughran and Big Brother Watch demonstrate important principles concerning genetic privacy, automated decisions, personal data and algorithmic accountability.

Ultimately, AI should support scientific research without replacing the legal, ethical and professional responsibilities of biotechnology institutions. Morocco's future regulatory development will need to balance technological innovation with privacy, human dignity, scientific reliability, public health and environmental protection.

16. Important Legal References and Research Sources

The following primary and secondary materials are useful for further academic research:

Moroccan Constitution, 2011, Articles 24 and 27.

Law No. 09-08 on Personal Data Protection.

Law No. 12-01 on Private Medical Biology Laboratories.

Law No. 11-08 on In Vitro Diagnostic Reagents.

Law No. 84-12 on Medical Devices.

Law No. 17-04 on the Code of Medicines and Pharmacy.

Law No. 05-20 on Cybersecurity.

Law No. 17-97 on Industrial Property.

Cartagena Protocol on Biosafety, 2000.

European Convention on Human Rights, Article 8.

Official and research resources:

Moroccan CNDP – Personal Data Protection Legislation.

Moroccan Ministry of Health – Health Products Regulation.

Moroccan Ministry of Health – Laboratory Legislation.

Morocco – Cartagena Protocol Implementation.

Chambers – Morocco Data Protection and Privacy 2026.

Morocco – National Biosafety Legislative Framework.

Academic research note: The five judicial decisions discussed above are comparative European authorities, not Moroccan court judgments. No directly reported Moroccan judgment establishing a precedent on AI integration in biotechnology laboratories has been identified in the sources reviewed. This distinction is essential when using the material in a dissertation, legal article or research paper.